Overall verdict
Sell
3.2/10
1-year performance
-51.67%
Score breakdown
Down 51.7% over 1 year, 1% of the 52-week range.
Strongest: Growth 6.7/10. Weakest: Shareholder return 0.0/10.
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes ; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid leukemia and hematologic malignancies ;
and ORM-1023, which is in pre-clinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It is also involved in the development of multiple programs for the treatment of solid tumors and immunology and inflammation; and E3 Ligase-DAC adaptor, an adaptor linker platform that conjugates protein degraders to antibodies and enables E3 ligase-based DACs. The company was founded in 2016 and is headquartered in Daejeon, South Korea.
Sector
Health Care
Industry
Biotechnology
Primary listing
Krx
South Korea
CEO
Sung-Joo Lee
Founded
2016
Employees
21
Revenue / employee
1.1M KRW
Next earnings
—
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
146600.00 KRW
52-week low
15690.00 KRW
1-year performance
-51.67%
Declining
Year-to-date performance
-85.81%
Declining
Drawdown
-88.44%
Major drawdown
Position in the 52-week range
1% of range
Gross margin -17045.1%, net margin 45646.4%, ROIC 9.5%, ROE 10.8%.
Net margin
45646.43%
Exceptional
Sector -224.99%|S&P 13.15%
Gross margin
-17045.09%
Negative
Return on equity (ROE)
10.79%
Fair
Sector -58.98%|S&P 16.61%
Return on invested capital (ROIC)
9.52%
Low
Free cash flow margin (FCF)
-130052.36%
Negative
Profit-to-cash conversion (FCF conversion)
-2.85x
Low
Growth
6.7/10Revenue up 479.1% over 1 year.
Revenue (trailing 12 months)
37.7M KRW
Revenue growth (1y)
479.07%
Hyper-growth
Revenue growth (3y)
-68.96%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.4/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
19.6x
Expensive
Sector 11.3x|S&P 24.1x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 14.4x|S&P 15.2x
PEG
—
Sector 1.09|S&P 0.90
Market cap
372Md KRW
Financial strength
5.9/10Cash covers 261.9% of the debt, net debt/EBITDA 2.5x.
Net debt / EBITDA
2.5x
Tight
Gearing (net debt / equity)
-83.71%
Net cash
Cash
234Md KRW
Cash / market cap
62.97%
Very solid
Cash / total debt
261.86%
Net cash
Interest coverage
-27.5x
Stretched
Net debt
-145Md KRW
Equity
173Md KRW
Closed daily candles, 20 months
Last close on October 21, 2026: 17,200.00 KRW
- MM2021,240.50
- MM5045,227.20
- MM20077,499.30
- RSI 1425.6
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-6.98%
200-day average slope, 3 months
-3.40%
50-day average slope, 1 month
-18.03%
Price structure
Lower lows
Bullish RSI divergence
Yes
20-day volatility
9.19 % per day
Volatility change
+33.33%
Same sub-industry: 781 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AGEN | 5.6 | 4.9 | 289M USD | 2.4x | 69.3 % | 34.4 % | -11.7 % | 6.7x | -34.1 % | 44.8 % | ||
| 2 | SRZN | 5.5 | 4.3 | 298M USD | Not meaningful (loss) | -3042.9 % | 408.6 % | — | 2.2x | -11.8 % | 87.6 % | ||
| 3 | 6915 | 4.9 | 4.9 | 285M USD | — | — | 6.7 % | — | -0.7x | — | -7.8 % | ||
| 4 | PRLD | 4.7 | 3.5 | 291M USD | Not meaningful (loss) | -269.7 % | 73.4 % | -50.5 % | 2.0x | -11.4 % | 182.9 % | ||
| 5 | BNTC | 4.4 | N/A | 297M USD | Not meaningful (loss) | — | — | -33.1 % | 3.5x | -5.9 % | -46.2 % | ||
| 6 | NWBO | 3.5 | 4.0 | 281M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.7 % | -25.0 % | ||
| 7 | IPSC | 3.4 | 1.5 | 292M USD | Not meaningful (loss) | -100.6 % | 1556.8 % | -41.9 % | 0.9x | -30.2 % | 182.2 % | ||
| 8 | A475830 | 3.2 | 3.3 | 281M USD | 19.6x | 45646.4 % | 479.1 % | 9.5 % | 2.5x | -13.2 % | -51.7 % | ||
| 9 | XFOR | 3.2 | 3.0 | 298M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -4.4 % |
